Leveraging the activity of tumor vaccines with cytotoxic chemotherapy
- PMID: 16166275
- DOI: 10.1158/0008-5472.CAN-05-1797
Leveraging the activity of tumor vaccines with cytotoxic chemotherapy
Abstract
Engaging the power of the patient's own immune system to actively seek out and destroy transformed cells holds great promise for cancer therapy. Tumor vaccines offer the potential for preventing cancer in high-risk individuals, preventing disease relapse after diagnosis and initial therapy, and shifting the balance of the host-tumor interaction to mitigate the progression of advanced cancers. The therapeutic activity of tumor vaccines is limited by the sheer physical burden of the cancer itself, pathways of local immune tolerance and escape active within the tumor microenvironment, and superimposed potent systemic mechanisms of immune tolerance. In this review, we describe how cytotoxic chemotherapy can be integrated with tumor vaccines using unique doses and schedules to break down these barriers, releasing the full potential of the antitumor immune response to eradicate disease.
Similar articles
-
Roadmap to a better therapeutic tumor vaccine.Int Rev Immunol. 2006 Sep-Dec;25(5-6):415-43. doi: 10.1080/08830180600992423. Int Rev Immunol. 2006. PMID: 17169782 Review.
-
Marrying immunotherapy with chemotherapy: why say IDO?Cancer Res. 2005 Sep 15;65(18):8065-8. doi: 10.1158/0008-5472.CAN-05-2213. Cancer Res. 2005. PMID: 16166276 Review.
-
Cancer immunotherapy.Biotechnol J. 2006 Feb;1(2):138-47. doi: 10.1002/biot.200500044. Biotechnol J. 2006. PMID: 16892244 Review.
-
Combined chemoimmunotherapy of solid tumours: improving vaccines?Adv Drug Deliv Rev. 2006 Oct 1;58(8):975-90. doi: 10.1016/j.addr.2006.04.002. Epub 2006 Aug 15. Adv Drug Deliv Rev. 2006. PMID: 17005292 Review.
-
Chemotherapy: friend or foe to cancer vaccines?Curr Opin Mol Ther. 2001 Feb;3(1):77-84. Curr Opin Mol Ther. 2001. PMID: 11249735 Review.
Cited by
-
Role of vaccine therapy in cancer: biology and practice.Curr Oncol. 2007 Dec;14(6):238-45. doi: 10.3747/co.2007.158. Curr Oncol. 2007. PMID: 18080016 Free PMC article.
-
Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism.J Immunol. 2009 Jul 1;183(1):137-44. doi: 10.4049/jimmunol.0900734. Epub 2009 Jun 17. J Immunol. 2009. PMID: 19535620 Free PMC article.
-
Immunoenhancing of the anti-cancer therapy and anti-oxidative stress by co-administration of granulocyte-colony stimulating factor-mobilized stem cells or cells derived from bone marrow and/or spleen plus vaccination with chemotherapeutic cyclophosphamide.Immunol Res. 2025 Mar 17;73(1):62. doi: 10.1007/s12026-025-09610-z. Immunol Res. 2025. PMID: 40091102
-
Dual role of immunomodulation by anticancer chemotherapy.Nat Med. 2013 Jan;19(1):20-2. doi: 10.1038/nm.3045. Nat Med. 2013. PMID: 23296003 Free PMC article.
-
Dose-dense chemotherapy improves mechanisms of antitumor immune response.Cancer Res. 2013 Jan 1;73(1):119-27. doi: 10.1158/0008-5472.CAN-12-2225. Epub 2012 Oct 29. Cancer Res. 2013. PMID: 23108141 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources